Key result
In a 38-year-old woman with paroxysmal atrial fibrillation, palpitations were more frequent in the follicular phase than the luteal phase.
Why the study?
Does periodic administration of antiarrhythmic medication based on the menstrual cycle improve symptoms of paroxysmal atrial fibrillation in a premenopausal woman?
Case Report (n=1)
Does periodic administration of antiarrhythmic medication based on the menstrual cycle improve symptoms of paroxysmal atrial fibrillation in a premenopausal woman?
Symptoms of paroxysmal atrial fibrillation in a premenopausal woman varied with the menstrual cycle, suggesting parasympathetic dependence, and were managed effectively with periodic medication administration.
Answers are grounded in this paper and cite their sources.
Menstrual cycle-linked symptom variation in premenopausal paroxysmal AF is hypothesis-generating; leaves open whether cycle-timed therapy improves outcomes.
Atrial fibrillation, an arrhythmia observed more frequently in men than women, is induced by both sympathetic and parasympathetic autonomic nerve activations. The menstrual cycle in premenopausal women has been reported to modulate the autonomic nervous system: parasympathetic activity is dominant in the follicular phase and sympathetic activity is dominant in the luteal phase. However, the relationship between atrial fibrillation and the menstrual cycle has not yet been reported, because this arrhythmia is very rarely detected in premenopausal women. We experienced a 38 year-old woman with paroxysmal atrial fibrillation. Her menstrual cycle was 30.4 ± 0.5 days and the menstrual period was 3.9 ± 0.2 days for 22 cycles. Although she had taken flecainide 200 mg/day, bepridil 200 mg/day, and propranolol 20 mg/day, she sometimes experienced mild palpitations. QTc intervals measured at her visits to our clinic were 440 ± 3 msec in the follicular phase and 425 ± 2 msec in the luteal phase (P = 0.01). These changes in QTc intervals during the menstrual cycle are compatible with earlier reports. During the 22 menstrual cycles, she felt palpitations on 3.2 ± 0.7 days in the menstrual period, 6.4 ± 0.3 days in the follicular phase, and 4.1 ± 0.4 days in the luteal phase (P = 0.01). Afterward, the medication was changed from daily to periodic administration for one week beginning a couple of days before the expected menstrual time, and she did not feel symptomatic variation in her menstrual cycle. These data suggest that her symptoms related to atrial fibrillation might have been dependent on parasympathetic activity.
No takes yet. Share an insight, caveat, or question.
Sugishita et al. (2013) conducted a case report in Paroxysmal atrial fibrillation (n=1). Periodic administration of antiarrhythmic medication vs. Daily administration was evaluated on Days with palpitations across menstrual cycle phases (p=0.01). In a 38-year-old woman with paroxysmal atrial fibrillation, palpitations were more frequent in the follicular phase than the luteal phase.
Synapse has enriched 10 related papers. Consider them for comparative context: